Fermavir Pharmaceuticals, Inc. Watch

from 8-K 3 pages Article Two Miscellaneous

from 8-K 11 pages Security Agreement

from 8-K 33 pages Note Purchase Agreement by and Between Fermavir Pharmaceuticals, Inc., and Inhibitex, Inc. Dated as of April 9, 2007

from 425 ~5 pages Fermavir Pharmaceuticals, Inc. 12% Senior Secured Promissory Note

from 425 ~10 pages Security Agreement

from 425 ~20 pages Note Purchase Agreement by and Between Fermavir Pharmaceuticals, Inc., and Inhibitex, Inc. Dated as of April 9, 2007

from 10QSB 3 pages Fermavir Pharmaceuticals, Inc. Amendment Agreement

from 10QSB 3 pages Fermavir Pharmaceuticals, Inc. Amendment Agreement

from 8-K 2 pages Agreement of Termination

from 8-K 2 pages Agreement of Termination

from 8-K 24 pages Securities Purchase Agreement

from 8-K 8 pages Debt Conversion Agreement

from 8-K 1 page (B) in the Event the Trigger Event Occurs, I Agree That Upon Exercise of the Company’s Option Set Forth in Section 2a of the Repurchase Agreement and the Payment to Me of $50,000, the Company Will Cancel 472,500 Options to Purchase the Company’s Common Stock Represented by Option No. 0-Fermavir-05-A-003. in Addition, Pursuant to Section 2.4 of the Taa, Within Thirty (30) Days After the Exercise Notice (As Defined in the Taa) Has Become Effective, the Company Shall Transfer, in Exchange for the Consideration Set Forth in Section 2.3 of the Taa, All Rights, Title and Interest in and to the Core Technology (As Defined in the Taa), Without Any Encumbrance or Lien (But Subject to Any Development or Research Right or Licenses Granted by the Company Prior to the Exercise Date (As Defined in the Taa) and the Payment of the Purchase Note (As Defined in the Taa)), and the Company Will Deliver the Core Technology, Including Any Documentation Thereto, to the Holders or Any Assignee of the Holders, Including, Without Limitation, University Cardiff Consultants Limited, as Directed in the Exercise Notice

from 8-K 1 page (B) in the Event the Trigger Event Occurs, I Agree That Upon Exercise of the Company’s Option Set Forth in Section 2a of the Repurchase Agreement, Upon Payment to Me of $50,000, the Company Will Cancel 472,500 Options to Purchase the Company’s Common Stock Represented by Option No. 0-Fermavir-05-A-002. in Addition, Pursuant to Section 2.4 of the Taa, Within Thirty (30) Days After the Exercise Notice (As Defined in the Taa) Has Become Effective, the Company Shall Transfer, in Exchange for the Consideration Set Forth in Section 2.3 of the Taa, All Rights, Title and Interest in and to the Core Technology (As Defined in the Taa), Without Any Encumbrance or Lien (But Subject to Any Development or Research Right or Licenses Granted by the Company Prior to the Exercise Date (As Defined in the Taa) and the Payment of the Purchase Note (As Defined in the Taa)), and the Company Will Deliver the Core Technology, Including Any Documentation Thereto, to the Holders or Any Assignee of the Holders, Including, Without Limitation, University Cardiff Consultants Limited, as Directed in the Exercise Notice

from 8-K 10 pages Technology Acquisition Agreement

from 8-K 13 pages Fermavir Pharmaceuticals, Inc. Repurchase Option Agreement

from 8-K 9 pages Executive Employment Agreement

from SB-2 17 pages Patent and Technology License Agreement

from SB-2 51 pages Agreement of Lease Between Slg Graybar Sublease LLC Landlord and Fermavir Research, Inc. Tenant Dated as of July 1, 2005 Room 445-47 420 Lexington Avenue New York, New York

from 8-K 7 pages Letter of Engagement Fermavir Pharmaceuticals, Inc. December 12, 2005